Bolivia is an emerging, cost-effective clinical research market. AGEMED (Agencia Estatal de Medicamentos y Tecnologías en Salud), under the Ministry of Health and Sports, is responsible for registration, surveillance, and authorization. In 2025 AGEMED optimized its procedures for research authorization. The pathway combines AGEMED authorization, an investigational device import permit, and IRB/ethics approval under ISO 14155 and the Declaration of Helsinki. With bioaccess®'s coordination, sponsors generate FDA-submissible data at ~30% lower cost than US/EU programs.
Bolivia is an emerging clinical research market that offers a cost-effective option for first-in-human medical device studies. Its national regulator is AGEMED (Agencia Estatal de Medicamentos y Tecnologías en Salud — National Agency of Medicines and Health Technologies), which operates under the Ministry of Health and Sports and is responsible for registration, surveillance, and authorization of health products and research.
In 2025, AGEMED optimized its procedures for research authorization, improving predictability for sponsors. The FIH pathway combines AGEMED authorization, an investigational device import permit, and IRB/ethics approval before enrollment can begin. Studies are conducted under ISO 14155 and the Declaration of Helsinki.
bioaccess® coordinates AGEMED submissions, ethics committee review, site qualification, and monitoring so sponsors get FDA-quality first-in-human data at roughly 30% lower cost than a comparable US or EU program. Bolivia fits well within multi-country LATAM programs and for cost-conscious FIH strategies.
AGEMED (Agencia Estatal de Medicamentos y Tecnologías en Salud) is Bolivia's national agency for medicines and health technologies, operating under the Ministry of Health and Sports. AGEMED is responsible for registration, surveillance, and authorization of health products and research. bioaccess® prepares complete AGEMED dossiers and coordinates directly with the agency through study start-up.
Every clinical study in Bolivia must be approved by an IRB / ethics committee before enrollment can begin. Ethics review follows ISO 14155 and the Declaration of Helsinki, evaluating scientific merit, risk-benefit balance, informed consent, and patient protection. bioaccess® coordinates ethics submissions with partner committees.
In 2025, AGEMED optimized its procedures for research authorization, improving predictability for sponsors planning early-phase device work in Bolivia. FIH device programs also require an investigational device import permit alongside AGEMED authorization and IRB/ethics approval.
Under 21 CFR 812.28, foreign clinical data is eligible for FDA submission and review from Bolivia for IDE submissions and marketing applications when studies are conducted under ISO 14155 with proper AGEMED authorization and ethics approval. bioaccess® designs every protocol for FDA submission from day one.
| Metric | Bolivia 🇧🇴 | United States 🇺🇸 | Europe (EU) 🇪🇺 |
|---|---|---|---|
| Regulatory authority | AGEMED (Min. of Health & Sports) | FDA | EMA / national CAs |
| Ethics review | IRB / ethics committee approval | Local IRBs | Per-country ECs |
| Regulatory momentum | 2025 procedure optimization | Established | Established |
| FDA data acceptance | Eligible for submission/review — 21 CFR 812.28 (ISO 14155) | Native | Yes, with justification |
| Cost vs. US program | ~30% lower | Baseline | ~15–25% lower |
| Market maturity | Emerging | Established | Established |
Regulatory details reflect published national frameworks; timelines and costs vary by device complexity, therapeutic area, and monitoring requirements. bioaccess® confirms the current pathway for each program.
AGEMED (Agencia Estatal de Medicamentos y Tecnologías en Salud), under the Ministry of Health and Sports, is Bolivia's national agency responsible for registration, surveillance, and authorization of health products and research.
Every study must be approved by an IRB / ethics committee before enrollment begins. Ethics review follows ISO 14155 and the Declaration of Helsinki.
AGEMED optimized its procedures for research authorization in 2025, improving predictability for sponsors. FIH device programs require AGEMED authorization, an investigational device import permit, and IRB/ethics approval under ISO 14155.
Yes. Under 21 CFR 812.28, foreign clinical data is eligible for FDA submission and review from Bolivia when studies are conducted under ISO 14155 with proper AGEMED authorization and ethics approval. bioaccess® designs protocols for FDA submission from the start.
Bolivia programs typically run ~30% lower than a comparable US or EU program. Actual cost depends on device complexity, indication, monitoring intensity, and sample size — bioaccess® scopes each program individually.
Bolivia combines a defined AGEMED pathway, recent 2025 procedure optimization for research authorization, ISO 14155-aligned ethics review, and ~30% lower program cost than US/EU baselines — making it a strong emerging-market option for cost-conscious FIH strategies.
All countries we serve · Contact bioaccess® · First-in-Human CRO